<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33587403</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1533-712X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>2</Issue>
            <PubDate>
              <MedlineDate>2021 Mar-Apr 01</MedlineDate>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical psychopharmacology</Title>
          <ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults.</ArticleTitle>
        <Pagination>
          <StartPage>155</StartPage>
          <EndPage>162</EndPage>
          <MedlinePgn>155-162</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000001361</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Viloxazine extended-release is a novel nonstimulant under investigation as a potential treatment for attention-deficit/hyperactivity disorder (ADHD). Given the potential for viloxazine extended-release to be co-administered with stimulant ADHD pharmacotherapies, this trial investigated the pharmacokinetics and safety of combination viloxazine extended-release + lisdexamfetamine dimesylate (lisdexamfetamine) versus viloxazine extended-release and lisdexamfetamine alone.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this single-center, cross-over, open-label trial, healthy, non-ADHD adults received single oral doses of 700 mg viloxazine extended-release alone, 50 mg lisdexamfetamine alone, and a combination of viloxazine extended-release (700 mg) + lisdexamfetamine (50 mg), with blood samples collected over 4 days postadministration. The active drug in viloxazine extended-release (viloxazine) and primary metabolite of lisdexamfetamine (d-amphetamine) were measured using chromatographic tandem mass spectrometry. Safety assessments included adverse events, vital signs, echocardiograms, and clinical laboratory evaluations.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-six adults were enrolled, and 34 completed the trial. The least squares geometric mean ratios are reported as [combination / single drug (90% confidence intervals)]. Viloxazine extended-release: Cmax = 95.96% (91.33-100.82), area under the concentration-time curve from 0 to the last measurable time (AUC0-t) = 99.19% (96.53-101.91), and area under the concentration-time curve from 0 to infinity (AUCinf) = 99.23% (96.61-101.93). Lisdexamfetamine: Cmax = 112.78% (109.93-115.71), AUC0-t = 109.64% (105.25-114.22), and AUCinf = 109.52% (105.19-114.03). All reported adverse events, except 1 (moderate vomiting), were mild in severity.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Co-administration of viloxazine extended-release and lisdexamfetamine did not impact the pharmacokinetics of viloxazine or d-amphetamine relative to administration of either drug alone. After single dose administration, the combination appeared to be safe and well tolerated.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Faison</LastName>
            <ForeName>Shamia L</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Research, Supernus Pharmaceuticals, Inc., Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fry</LastName>
            <ForeName>Nicholas</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Research, Supernus Pharmaceuticals, Inc., Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adewole</LastName>
            <ForeName>Toyin</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Research, Supernus Pharmaceuticals, Inc., Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Odebo</LastName>
            <ForeName>Oyinkansola</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Research, Supernus Pharmaceuticals, Inc., Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Research, Supernus Pharmaceuticals, Inc., Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maletic</LastName>
            <ForeName>Vladimir</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry/Behavioral Science, University of South Carolina School of Medicine, Greenville, SC.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Research, Supernus Pharmaceuticals, Inc., Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Psychopharmacol</MedlineTA>
        <NlmUniqueID>8109496</NlmUniqueID>
        <ISSNLinking>0271-0749</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018759">Adrenergic Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SJT761GEGS</RegistryNumber>
          <NameOfSubstance UI="D000069478">Lisdexamfetamine Dimesylate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018759" MajorTopicYN="N">Adrenergic Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069478" MajorTopicYN="N">Lisdexamfetamine Dimesylate</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="N">Viloxazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>13</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33587403</ArticleId>
        <ArticleId IdType="pmc">PMC7919699</ArticleId>
        <ArticleId IdType="doi">10.1097/JCP.0000000000001361</ArticleId>
        <ArticleId IdType="pii">00004714-202103000-00012</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Adesman AR. The diagnosis and management of attention-deficit/hyperactivity disorder in pediatric patients. Prim Care Companion J Clin Psychiatry. 2001;3:66–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC181164</ArticleId>
            <ArticleId IdType="pubmed">15014618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banaschewski T Becker K Dopfner M, et al. . Attention-deficit/hyperactivity disorder: a current overview. Dtsch Arztebl Int. 2017;114:149–159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5378980</ArticleId>
            <ArticleId IdType="pubmed">28351467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A Yeh CJ Verma N, et al. . Overview of attention deficit hyperactivity disorder in young children. Health Psychol Res. 2015;3:2115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4768532</ArticleId>
            <ArticleId IdType="pubmed">26973960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danielson ML Bitsko RH Ghandour RM, et al. . Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47:199–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5834391</ArticleId>
            <ArticleId IdType="pubmed">29363986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessler RC Adler L Barkley R, et al. . The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716–723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2859678</ArticleId>
            <ArticleId IdType="pubmed">16585449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polanczyk G de Lima MS Horta BL, et al. . The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17541055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon V Czobor P Balint S, et al. . Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19252145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briars L, Todd T. A review of pharmacological management of attention-deficit-hyperactivity disorder. J Pediatr Pharmacol Ther. 2016;21:192–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4956327</ArticleId>
            <ArticleId IdType="pubmed">27453697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Catala-Lopez F Hutton B Nunez-Beltran A, et al. . The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12:e0180355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5507500</ArticleId>
            <ArticleId IdType="pubmed">28700715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adler LA Reingold LS Morrill MS, et al. . Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8:409–415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16968624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molife C Bernauer MJ Farr AM, et al. . Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations. Postgrad Med. 2012;124:7–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23095422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens TE Spencer T Biederman J, et al. . Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 1995;34:110–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7860450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J Wilens T Mick E, et al. . Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152:1652–1658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7485630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65(suppl 3):38–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15046534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soutullo CA DelBello MP Ochsner JE, et al. . Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. J Affect Disord. 2002;70:323–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12128245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corkum P Moldofsky H Hogg-Johnson S, et al. . Sleep problems in children with attention-deficit/ hyperactivity disorder: impact of subtype, comorbidity, and stimulant medication. J Am Acad Child Adolesc Psychiatry. 1999;38:1285–1293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10517062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nafees B Setyawan J Lloyd A, et al. . Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry. 2014;23:1189–1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4246123</ArticleId>
            <ArticleId IdType="pubmed">24443092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med. 2014;126:64–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25295651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens TE Adler LA Adams J, et al. . Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:21–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18174822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C Garcia-Olivares J Candler S, et al. . New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viloxazine, CID=5666. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Viloxazine. Accessed January 17, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Williams D. Antidepressants. In: Lemke TL Williams DA Roche VF, et al.., eds. Foye's Principles of Medicinal Chemistry. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Bereen FJ. A new potential antidepressive. Lancet. 1973;301:379–380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4121981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson JK Liranso T Saylor K, et al. . A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24:348–358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6939319</ArticleId>
            <ArticleId IdType="pubmed">30924702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinder RM Brogden RN Speight TM, et al. . Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;13:401–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">324751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A Liranso T Adewole T, et al. . A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42:1452–1466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A Liranso T Adewole T, et al. . Once-Daily 200-mg and 400-mg SPN-812 in the Treatment of ADHD in School-Age Children: A Phase 3 Randomized Controlled Trial). Clin Ther. In press.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A Hull JT Chowdhry F, et al. . Extended-release viloxazine (SPN-812) 200 mg or 400 mg for the treatment of ADHD in adolescents: Topline results of a phase 3, randomized, double-blind, placebo-controlled study (P302). Presented at 32nd Annual Psych Congress. October 3–6, 2019, 2019; San Diego (CA).</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A Liranso T Adewole T, et al. . A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD. Psychopharm Bull. 2021;51:1–22.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50:1285–1300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32394778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roesch B Corcoran ME Fetterolf J, et al. . Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. Drugs R D. 2013;13:119–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3689918</ArticleId>
            <ArticleId IdType="pubmed">23615868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2898170</ArticleId>
            <ArticleId IdType="pubmed">20628632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bach MV, Coutts RT, Baker GB. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999;29:719–732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10456690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet. 2001;40:753–772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11707061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markowitz JS, Patrick KS. The clinical pharmacokinetics of amphetamines utilized in the treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27:678–689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28910145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer T Biederman J Wilens T, et al. . Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35:409–432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8919704</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
